Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for remifentanil (compound)

Name: remifentanil
PubChem Compound ID: 60814
Molecular formula: C20H29ClN2O5
Molecular weight: 412.907 g/mol
1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester, monohydrochloride; Ultiva; Ultiva (TN); GI-87084B; 4-Carboxy-4-(N-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride; GI 87084B; 132539-07-2; D01177; Remifentanil hydrochloride; Remifentanil hydrochloride [USAN].
show more »
Name: remifentanil
Name (isomeric): DB00899
Drug Type: small molecule
Brand: Ultiva
Category: Anesthetics, Intravenous, Hypnotics and Sedatives, Analgesics, Opioid
CAS number: 132875-61-7
Indication: For use during the induction and maintenance of general anesthesia.
Remifentanil is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifenta...
show more »
Mechanism of Action: Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
Protein binding: 70% (bound to plasma proteins)
Biotransformation: By hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases.
Route of elimination: Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
Half Life: 1-20 minutes
Clearance: 40 mL/min/kg [young, healthy adults]
Affected organisms: Humans and other mammals
Drug interaction:
TriprolidineThe CNS depressants, Triprolidine and Remifentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
TranylcyprominePossible increased risk of serotonin syndrome.